As worldwide markets for electric vehicles continue to gain market share, low-cost connections of vehicles to mains charging need to be safe and efficient.

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...

Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. Despite the success of Enhertu, the company has experienced two latest hiccups: the discontinuation of internal ...

6 analysts have issued ratings. Wall Street analysts rate ADCT as Very Bullish on average, for a Wall Street consensus of buy. View ADCT’s ratings here. ADC Therapeutics SA is currently listed on NYSE ...

This is the development repository of the CMSIS-Driver interface to STM32Cube HAL (called Driver API Shim Interface below). User applications and middleware components use CMSIS-Driver to achieve ...

Abstract: Compact, high-bandwidth analog-to-digital converters (ADCs) with moderate resolution are a critical building block in high-speed communication links. In this work, a hybrid time and voltage ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...

Abstract: This paper proposes a passive switched-capacitor single-ended-to-differential-converter (SDC) as a front-end of a differential SAR ADC, such that it can convert single-ended input signals.

This is a simple server that scrapes Citrix ADC stats and exports them via HTTP to Prometheus. Prometheus can then be added as a data source to Grafana to view the Citrix ADC stats graphically. Now ...

Antibody–drug conjugates (ADCs) combine the targeting ability of monoclonal antibodies with the cell-killing effects of potent cytotoxic drugs. Over the past decade, the approach has moved from ...